These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 14693080)

  • 1. Putting theory into practice: a challenging case study in the treatment of depression.
    J Fam Pract; 2003 Dec; Suppl():S63-70. PubMed ID: 14693080
    [No Abstract]   [Full Text] [Related]  

  • 2. Citalopram versus amitriptyline in elderly depressed patients with or without mild cognitive dysfunction: a danish multicentre trial in general practice.
    Rosenberg C; Lauritzen L; Brix J; Jørgensen JB; Kofod P; Bayer LB
    Psychopharmacol Bull; 2007; 40(1):63-73. PubMed ID: 17285097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The intensity dependence of the auditory evoked N1 component as a predictor of response to Citalopram treatment in patients with major depression.
    Linka T; Müller BW; Bender S; Sartory G
    Neurosci Lett; 2004 Sep; 367(3):375-8. PubMed ID: 15337269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diurnal mood variation in outpatients with major depressive disorder.
    Morris DW; Trivedi MH; Fava M; Wisniewski SR; Balasubramani GK; Khan AY; Jain S; Rush AJ
    Depress Anxiety; 2009; 26(9):851-63. PubMed ID: 19306304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety.
    Olié JP; Tonnoir B; Ménard F; Galinowski A
    Depress Anxiety; 2007; 24(5):318-24. PubMed ID: 17041922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [An episode of depression in a patient with coronary artery disease].
    Dudek D; Dudek D; Zieba A
    Psychiatr Pol; 2001; 35(5):797-802. PubMed ID: 11842611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Open-label study of s-citalopram therapy of chronic fatigue syndrome and co-morbid major depressive disorder.
    Amsterdam JD; Shults J; Rutherford N
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):100-6. PubMed ID: 17804135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
    Demyttenaere K; Hemels ME; Hudry J; Annemans L
    Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Severe forms of depression: the efficacy of escitalopram].
    Spadone C
    Encephale; 2009 Apr; 35(2):152-9. PubMed ID: 19393384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.
    Langworth S; Bodlund O; Agren H
    J Clin Psychopharmacol; 2006 Apr; 26(2):121-7. PubMed ID: 16633139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.
    Leuchter AF; Cook IA; Gilmer WS; Marangell LB; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; Fava M; Iosifescu D; Greenwald S
    Psychiatry Res; 2009 Sep; 169(2):132-8. PubMed ID: 19709754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Citalopram-associated spontaneous ejaculations.
    Virit O; Savas HA
    J Clin Psychopharmacol; 2008 Jun; 28(3):360-1. PubMed ID: 18480704
    [No Abstract]   [Full Text] [Related]  

  • 13. Dysfunctional attitudes and perceived stress predict depressive symptoms severity following antidepressant treatment in patients with chronic depression.
    Pedrelli P; Feldman GC; Vorono S; Fava M; Petersen T
    Psychiatry Res; 2008 Dec; 161(3):302-8. PubMed ID: 18976817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment.
    Papiol S; Arias B; Gastó C; Gutiérrez B; Catalán R; Fañanás L
    J Affect Disord; 2007 Dec; 104(1-3):83-90. PubMed ID: 17467808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial.
    Chokka P; Legault M
    Depress Anxiety; 2008; 25(12):E173-81. PubMed ID: 19006260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open-label multicentric study of the tolerability and response to escitalopram treatment in Indian patients with major depressive disorder.
    Pinto C; Trivedi JK; Vankar GK; Sharma PS; Narasimha V
    J Indian Med Assoc; 2007 Jul; 105(7):364, 366, 368 passim. PubMed ID: 18178988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychopharmacology of smoking cessation in patients with mental illness.
    Selby P
    J Psychiatry Neurosci; 2006 Sep; 31(5):360. PubMed ID: 16951737
    [No Abstract]   [Full Text] [Related]  

  • 18. Effective dose of escitalopram in moderate versus severe DSM-IV major depression.
    Bech P; Andersen HF; Wade A
    Pharmacopsychiatry; 2006 Jul; 39(4):128-34. PubMed ID: 16871468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Citalopram].
    Taéron C
    Rev Infirm; 2008 Nov; (145):47-9. PubMed ID: 19044198
    [No Abstract]   [Full Text] [Related]  

  • 20. Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome.
    Howland RH; Rush AJ; Wisniewski SR; Trivedi MH; Warden D; Fava M; Davis LL; Balasubramani GK; McGrath PJ; Berman SR
    Drug Alcohol Depend; 2009 Jan; 99(1-3):248-60. PubMed ID: 18986774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.